Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immunotherapy, and future directions
AKA Lalani, BA McGregor, L Albiges, TK Choueiri… - European urology, 2019 - Elsevier
Context Systemic therapy for metastatic clear cell renal cell carcinoma (mccRCC) has greatly
evolved over the last 15 yr. More recently, combination strategies involving contemporary …
evolved over the last 15 yr. More recently, combination strategies involving contemporary …
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
…, F Xu, A Butturini, LD Eli, G Mann, C Farrell, AS Lalani… - Nature, 2018 - nature.com
Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively)
are found in a wide range of cancers. Preclinical modelling suggests that a subset of these …
are found in a wide range of cancers. Preclinical modelling suggests that a subset of these …
Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition
…, C Castanaro, E Pasnikowski, A Adler, AS Lalani… - Cancer research, 2013 - AACR
The angiopoietins Ang1 (ANGPT1) and Ang2 (ANGPT2) are secreted factors that bind to the
endothelial cell–specific receptor tyrosine kinase Tie2 (TEK) and regulate angiogenesis. …
endothelial cell–specific receptor tyrosine kinase Tie2 (TEK) and regulate angiogenesis. …
TRAF molecules in inflammation and inflammatory diseases
Purpose of Review This review presents an overview of the current knowledge of tumor
necrosis factor receptor (TNF-R)-associated factor (TRAF) molecules in inflammation with an …
necrosis factor receptor (TNF-R)-associated factor (TRAF) molecules in inflammation with an …
[HTML][HTML] Preclinical characteristics of the irreversible pan-HER kinase inhibitor neratinib compared with lapatinib: implications for the treatment of HER2-positive and …
An estimated 15–20% of breast cancers overexpress human epidermal growth factor receptor
2 (HER2/ERBB2/neu). Two small-molecule tyrosine kinase inhibitors (TKIs), lapatinib and …
2 (HER2/ERBB2/neu). Two small-molecule tyrosine kinase inhibitors (TKIs), lapatinib and …
[HTML][HTML] Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
AKA Lalani, W Xie, DJ Martini, JA Steinharter… - … for immunotherapy of …, 2018 - Springer
Background An elevated Neutrophil-to-lymphocyte ratio (NLR) is associated with worse
outcomes in several malignancies. However, its role with contemporary immune checkpoint …
outcomes in several malignancies. However, its role with contemporary immune checkpoint …
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
…, M Little, B Qeriqi, G Weitsman, CJ Wilhem, AS Lalani… - Cancer discovery, 2020 - AACR
T-DM1 is clinically effective in lung cancers with amplification of or mutations in ERBB2 . This
activity is enhanced by cotreatment with irreversible pan-HER inhibitors, or ADC switching …
activity is enhanced by cotreatment with irreversible pan-HER inhibitors, or ADC switching …
Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers
…, JJ Gartner, L Jia, G Ivey, YF Li, M El-Gamil, A Lalani… - Cancer discovery, 2019 - AACR
TILs cultured from 62 of 75 (83%) patients with gastrointestinal cancers recognized neoantigens
encoded by 1.6% of somatic mutations expressed by autologous tumor cells, and 99% …
encoded by 1.6% of somatic mutations expressed by autologous tumor cells, and 99% …
Evaluation of the utility of radiography in acute bronchiolitis
OBJECTIVES: To determine the proportion of radiographs inconsistent with bronchiolitis in
children with typical presentation of bronchiolitis and to compare rates of intended antibiotic …
children with typical presentation of bronchiolitis and to compare rates of intended antibiotic …
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
…, KC Banks, RB Lanman, R Bryce, AS Lalani… - Clinical Cancer …, 2017 - AACR
Purpose: Based on promising preclinical data, we conducted a single-arm phase II trial to
assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/…
assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/…